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ABSTRACT
Chagas disease (CD) is caused by the protozoan Trypanosoma cruzi and it is mainly 
acquired through the vector route, however, blood transfusion and congenital transmission 
are implicated in the spread of the illness worldwide. The congenital route can occur at any 
stage of pregnancy and its frequency varies. In the Federal District, in Brazil, the frequency 
of T. cruzi infection in pregnant women and their offspring has not been updated. Thus, the 
aim of this study was to estimate the prevalence of T. cruzi infection in pregnant women 
and the rate of congenital transmission in the Federal District. A cross-sectional study was 
conducted to estimate the seroprevalence of T. cruzi from 2014 to 2016 in the population of 
pregnant women attended by the public health service throughout the Federal District and a 
descriptive cohort for the evaluation of congenital transmission. During the study, prenatal 
data of 98,895 women were consulted and pregnant women registered in 2016, presenting 
with positive T. cruzi serology, were part of the descriptive cohort. The estimated prevalence 
of T. cruzi infection in the three years was 0.19% and the congenital transmission rate was 
1/40 (2.5%). Our results have shown that, although the main routes of transmission of CD 
have been interrupted, there is still a risk of congenital transmission in the Federal District. 
This present study highlights the need for the continuous implementation of a screening 
program for pregnant women and timely treatment of infected newborns and children.
KEYWORDS: Chagas disease. Congenital transmission. Pregnant Women. Trypanosoma 
cruzi. Screening program.
INTRODUCTION
Chagas disease (CD) is caused by the protozoan parasite Trypanosoma cruzi 
and is considered a neglected tropical disease that affects about 6 to 7 million 
people worldwide1. In recent years, CD has emerged as an important global health 
problem due to migratory flows spreading the infection to non-endemic countries2. 
The main route of CD acquisition is through vector transmission, but there are other 
important routes such as through blood transfusion, consumption of contaminated 
food and congenital transmission3. In Brazil, effective measures were implemented to 
control the vector and transfusion transmission pathways, which led to a substantial 
reduction of new cases of CD4,5.
 
However, there are millions of chronic cases that 
need attention from health services and public policies and this is a persisting 
challenge. This group includes women of childbearing age who can transmit the 
parasite vertically to their offspring4,6.
The transmission of T. cruzi from infected mothers to their fetuses can occur 
at any stage of pregnancy and most cases of congenital CD are asymptomatic in 
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newborns7. The frequency of congenital transmission varies 
according to the evaluated region and the diagnostic tests 
used. In the American continent, the rate is of 2%, but in 
countries like Argentina, Bolivia and Mexico, it varies 
between 5% and 7%8. In Brazil, it is around 1.7%9.
The diagnosis of congenital transmission of T. cruzi 
begins with the detection of infection in pregnant women 
and is thereafter confirmed through the confirmation of 
the infection in the newborns of positive mothers. The 
diagnostic tests in pregnant women should be performed as 
soon as the pregnancy is confirmed, as any newborn of an 
infected mother is at risk of infection by the parasite10. Early 
diagnosis and treatment of the newborn are essential to 
reduce the risk of developing disabling chronic conditions11. 
Due to the non-inclusion of T. cruzi diagnosis in the 
prenatal serological screening in several Brazilian regions, 
asymptomatic cases of congenital transmission may be 
underestimated and consequently neglected12. 
The congenital transmission is a form of continuity and 
maintenance of CD. Therefore, knowing the frequency of 
this condition in women of childbearing age and newborns 
is extremely important as these data are scarce and outdated 
in the Federal District (FD)13. The aim of this study was 
to estimate the prevalence of T. cruzi infection in pregnant 
women attended by the public service of the FD and to 
determine the rate of congenital CD transmission.
MATERIALS AND METHODS
Study design and population
The study was conducted in the FD, which is the seat 
of the government where the Brazilian capital is situated. It 
is located in the Midwest of the country with an estimated 
population of 3,015,268 inhabitants14. A cross-sectional 
study was carried out in the first phase of the study. Data 
registered in the information system of the Diagnostic 
Institute of Brasília (FD Health Secretariat), the institution 
responsible for prenatal screening tests, were consulted for 
the extraction of information on pregnant women to enable 
the seroprevalence estimate. The population was composed 
of all pregnant women attended by the public health system 
in the prenatal care throughout the FD, between 2014 and 
2016, totaling 98,895 pregnant women. In the second phase, 
women registered in 2016 who tested positive during the 
prenatal care were invited through a phone call to participate 
in a descriptive cohort with the objective of evaluating 
the congenital transmission. A questionnaire on the 
demographic profile, place of birth, housing characteristics, 
socioeconomic and clinical data, knowledge, attitudes and 
practices regarding CD was applied to the women who had 
formally accepted to participate. In addition, blood samples 
were collected from mothers and their newborns. Newborns’ 
samples were collected after birth and after nine months 
of age. The samples were submitted to parasitological and 
serological tests. The application of the questionnaire and 
the collection of samples occurred between September 
2017 and June 2018.
Parasitological and serological diagnosis
The direct search of T. cruzi was carried out to evaluate 
the presence of the parasite in peripheral blood samples of 
mothers and newborns/ children. Samples were evaluated in 
serological tests for the detection of IgG and IgM antibodies 
anti-T. cruzi by an Immunoenzyme assay (ELISA) and 
an Indirect Hemagglutination test (HAI). The ELISA 
was performed with the kit GOLD ELISA CHAGAS 
(REM, Sao Paulo, Brazil) following the manufacturer’s 
recommendations. The HAI test was performed according to 
the CHAGATEST kit protocol (Wiener, Rosario, Argentina).
Statistical analysis
The collected data were entered into an Excel 
spreadsheet and analyzed by the SPSS software, version 22 
(SPSS Inc., Chicago, IL, USA). The descriptive analysis of 
the results determined the absolute and relative frequencies 
calculated for the categorical variables.
Ethical approval
The study was approved by the Research Ethics 
Committee of the Faculty of Medicine/UnB (CAAE 
Nº 67968717.5.0000.5558/2017). Informed consent was 
obtained from all the participants. 
RESULTS
A total of 98,895 pregnant women were tested during 
the prenatal care of whom 188 (0.19%) were positive for 
CD. The prevalence of T. cruzi infection in 2014, 2015 and 
2016 was 0.19% (52/25,871), 0.21% (74/35,790) and 0.17% 
(62/37,234) respectively. Most pregnant women were in the 
30 to 39 years age group (Table 1).
The geographic distribution of pregnant women in 
the FD was evaluated by the location of the prenatal 
care unit in the Administrative Region (AR). In the three 
years, Ceilandia was the AR that tracked the largest 
number of pregnant women, a total of 17,878 individuals, 
corresponding to most of the positive cases, 15.43% 
(29/188) (Figure 1).
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The descriptive cohort study was conducted with 
(42/62) of mothers who tested positive in 2016 and their 
43 babies. One woman died due to complications of CD 
and was excluded from the study. Concerning the housing 
characteristics, 50% of the interviewees reported having 
lived most of their lives in rural areas where there was no 
asphalt, treated water, sewage and garbage collection. For 
the socioeconomic variables, approximately 38% (16/42) 
had as profession/ occupation: “home secretary” (domestic 
worker), and (22/42) did not work. Most of the families 
income ranged from 1 to 3 minimum wages. Regarding 
the demographic variables, the majority came from Bahia 
State, Northeast of Brazil (Table 2).
In relation to knowledge, attitudes and practices 
regarding CD, more than 80% reported having knowledge 
about the disease and they knew how the disease can 
be acquired. However, the degree of uncertainty on 
transmission pathways such as blood transfusion/ organ 
donation and whether the disease could be acquired 
through the contact with a sick person was approximately 
33% each. The majority stated that they had knowledge 
about the triatomine, and when questioned on the contact 
with the insect vector (28/42- 66.7%) responded positively 
and (7/42- 16.7%) admitted that they had already been 
bitten by triatomines. Regarding the conduct when the 
vector is found in the home environment, more than 70% 
confirmed to have already killed the insect immediately 
after its detection. 
Regarding the knowledge on the positivity to T. cruzi 
infection, (28/42 -66.7%) said that they became aware 
Table 1 - Distribution by age group of T. cruzi-seropositive 
pregnant women attended by public health services in 2014, 
2015 and 2016. Federal District, Brazil.
Year Age group n %
2014
< 20 1/52 1.9
20-29 10/52 19.2
30-39 25/52 48.1
≥ 40 16/52 30.8
2015
< 20 2/74 2.7
20-29 9/74 12.1
30-39 47/74 63,6
≥ 40 14/74 18.9
Not reported 2/74 2.7
2016
< 20 1/62 1.6
20-29 9/62 14.5
30-39 42/62 67.7
≥ 40 10/62 16.1
Total 186 100
Figure 1 - Distribution of the number of seropositive cases by administrative region in the Federal District, Brazil, in 2014, 2015 
and 2016.
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during the prenatal care in 2016. Among the interviewees 
who already knew about the positivity, 50% were aware 
of the situation before the prenatal care. The mothers who 
said that they knew or suspected the possible route of 
infection (13/15) stated that it may have occurred due to 
the bite of the insect vector and (4/42- 9.5%) had already 
received blood transfusions. In respect to the clinical signs 
that could be related to CD, the most common complaints 
were: tiredness, tachycardia, arrhythmia and constipation. 
Most mothers with CD symptoms did not have or had any 
type of medical follow-up and around 45% received specific 
care in the private sector. Concerning the family history of 
CD, 69% responded positively. The results of the interviews 
are summarized in Table 3.
In relation to the seroprevalence in newborns, 40/43 
(93%) had the mother’s authorization for the blood 
collection. Of these, 97.5% (39/40) were negative, with a 
single positive case confirming  positive  serology  after 
9  months  of  age. The child was treated at the University 
Hospital of Brasilia, where the infant was evaluated and 
received antiparasitic treatment for 60 days. 
The direct parasitological test showed negative results 
for all tested samples of seropositive mothers and their 
children. 
DISCUSSION
Similar studies performed in Brazil have shown that the 
frequency of CD infection in pregnant women in Brazil is 
between 0.1 and 0.5%15-17. However, the prevalence found 
in our study is lower when compared to other countries in 
Latin America, whose rates range from 3.2 to 23.6%18-21. 
The high frequency found in pregnant women with more 
than 32 years of age is similar to other findings that have 
found age as a factor associated with the risk of infection 
by T.cruzi due to the accumulated exposure over the 
years18,22. 
The locality with the highest number of pregnant women 
screened and seropositive for T. cruzi was Ceilandia, the 
most populous region with a low per capita income in the 
FD23. Most immigrants in the FD (52.15%) came from the 
Northeast of Brazil and Ceilandia is home to the majority24. 
The level of education of the interviewees is higher than 
the general population of the FD, however, the family 
income was below the average and most are participants 
were unemployed24. The participants had lived or still live 
in places without asphalt, basic sanitation, and referred 
contact with cob walls or similar structures, supporting that 
seropositivity is more frequent among the less socially and 
economically favored population25. 
The main knowledge of mothers about CD was related 
to vector transmission. This is justifiable due to the contact 
with these insects during childhood. Regarding the lack of 
knowledge about CD symptoms, this may be related to the 
fact that most are asymptomatic. This lack of symptoms 
makes the search for health services less common and may 
be related to the fact that most of them become aware of 
their seropositivity only in the prenatal care. In addition, 
the scarcity of guidelines and the lack of information on 
the risk of congenital transmission by health professionals 
has been reported. These perceptions were also pointed 
out by Bolivian immigrants in Spain26. We observed that 
the interviewees did not know how to proceed correctly 
if they find the insect vector in the home environment. 
The knowledge of the community on how to behave if 
they find triatomines is extremely important and should 
be articulated to the practices of community collaboration 
with the surveillance and control agencies27.
In respect to the investigation of congenital transmission, 
our study showed 1/40 (2.5%) of seropositivity, corresponding 
to a single case in which the infant remained positive for 
antibodies against T. cruzi after nine months ofage. Given 
the exclusion of other routes of transmission and the age 
of the infant, it was possible to affirm that there was a case 
of congenital transmission. The frequency found remained 
within the national range28, which varied from 0 to 5.2%. 
Table 2 - Distribution of cases of T. cruzi-seropositive 
mothers according to demographics, socioeconomic data and 
educational level. Federal District, 2016.
Data (n) %
Federated unit of birth
   Distrito Federal/ Goias 4 9.5
   Para/Pernambuco/ Piaui 4 9.5
   Minas Gerais 4 9.5
   Maranhao 5 11.9
   Bahia 25 59.6
Educational level 
   Elementary school 17 40.4
   High school 18 42.9
   College 7 16.7
Familiar income (in minimum wages)
   Up to 1 (R$937.00) 5 11.8
   From 1 to 3 (R$937.00 to R$2,811.00) 22 52.4
   From 3 to 6 (R$2,811.00 to R$5,622.00) 9 21.4
   From 6 to 9 (R$5,622.00 to R$ 8,433.00) 2 4.8
   From 9 a 12 (R$8,433.00 to R$11,244.00) 2 4.8
   More than 12 (more than R$11,244.00) 1 2.4
   Do not know 1 2.4
Total 42 100
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The small number of mothers and babies evaluated can 
be considered a limitation of our study, as it was not possible 
to find all mothers due to the change of telephone numbers, 
home address or even moving to a different State. Studies 
performed with a larger sample can be more conclusive, 
however, it is worth mentioning that our study represents 
a first step in updating the data concerning the congenital 
transmission of CD in the FD, Brazil.
Better quality of life and prognosis of infected mothers 
in addition to timely treatment of congenital cases allowing 
high cure rates justify the efforts and the importance of 
prenatal screening programs. Serological screening for 
T. cruzi infection in the prenatal care has not yet been 
implemented at the national level. Consequently, due to 
the poor monitoring of pregnant women and their children 
especially in endemic regions, many cases of congenital 
transmission might be underreported and neglected in 
Brazil12.
In conclusion, the prevalence of pregnant women 
with T. cruzi infection and the frequency of congenital 
transmission shown in the present study were similar to 
other reports in Brazil. Prenatal screening is extremely 
important for the knowledge of positive cases in pregnant 
women. It allowed the identification of a case of congenital 
CD transmission in the FD, Brazil, which would probably 
be undetected as the child was asymptomatic and was not 
monitored by the health service. Our results highlight the 
need for the continuous implementation of a screening 
program for pregnant women and timely treatment for 
newborns and infected children in Brazil.
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